Eyeforpharma 2020 meeting goes virtual

Due to the Covid-19 outbreak, Eyeforpharma 2020 will be a completely virtual meeting—taking place April 14–17. Now more than ever, we need to share insights, collaborate, and connect virtually to tackle top-of-mind issues in health care. Advisory Board is looking forward to presenting our latest research—during a live session and available on-demand—bringing our insights directly to your desk.

Join our session: Rebranding Real-World Evidence

Real-world evidence (RWE) is an industry buzzword that’s anything but new. Payers and providers use RWE to inform decisions every day. But evangelists and critics paint very different pictures of what RWE is and isn’t.

Join our session at Eyeforpharma on Wednesday, April 15, at 11:00 am ET, “Rebranding Real-World Evidence: How to change how we talk about RWE and who accepts it,” where we’ll discuss the following:

  • Which customers are ready to accept RWE now—and why
  • Why customers are skeptical and how to address their concerns
  • What you can do to advance the RWE conversation now

  →  Register for FREE for Eyeforpharma

Fill out the form to network with us during Eyeforpharma 2020

*
*
*
*
*

A PREVIEW OF OUR PRESENTATION

WHO IS ADVISORY BOARD?

For more than 40 years, we've helped executives and future leaders in health care work smarter and faster by providing provocative insights, actionable strategies, and practical tools to support execution.

With 40+ years of experience, a team of 250+ experts, and a network of 4,900+ member organizations that span the payer, provider, and supplier industries, we support life sciences firms’ commercial and medical leaders with research and educational resources that develop market strategy, enrich customer insight, and more.

  →  More for life sciences medical leaders

  →  More for health care suppliers and service firms

OUR EXPERT PRESENTER


“I know of no other industry conference with an agenda so focused on facilitating conversations across pharma, payers, provider, and patients. I am excited to bring Advisory Board’s research on real-world evidence into these discussions.”